Revolution Medicines (RVMD) director exercises 120K options, sells 120K shares under 10b5-1 plan

Rhea-AI Filing Summary

Revolution Medicines, Inc. director and officer Mark A. Goldsmith exercised stock options and sold shares of common stock. He exercised options for 23,244 shares at an exercise price of $4.09 and 96,756 shares at $4.73, receiving an equal number of common shares. He then sold 120,000 common shares at a weighted average price of $150.0874 in open-market transactions made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. After these transactions, he held 276,698 common shares directly, including 201,150 restricted stock units, and additional indirect holdings through family trusts.

Insights

Equity compensation and insider-trading analyst

Goldsmith exercised options for 120,000 shares and sold the same amount under a pre-set 10b5-1 plan.

Mark A. Goldsmith exercised stock options for 23,244 shares at an exercise price of $4.09 and 96,756 shares at $4.73, converting previously granted derivatives into common stock. He then sold 120,000 common shares at a weighted average of $150.0874 on April 15, 2026.

The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on December 19, 2024, indicating they were pre-scheduled rather than timed opportunistically. Following the transactions, he still holds 276,698 common shares directly, including 201,150 restricted stock units, plus substantial indirect holdings through revocable trusts.

With derivativeSummary empty, this exercise appears to use up the related option positions reported here. The net effect is to monetize part of his equity while maintaining a significant ongoing stake. Future company filings may further detail any additional grants or changes in holdings.

Insider Trade Summary 10b5-1

Net Seller: 120,000 shares ($18,010,488)

Net Sell 8 txns

Insider GOLDSMITH MARK A

Role See Remarks

Sold 120,000 shs ($18.01M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	23,244	$0.00	--
Exercise	Stock Option (Right to Buy)	96,756	$0.00	--
Exercise	Common Stock	23,244	$4.09	$95K
Exercise	Common Stock	96,756	$4.73	$458K
Sale	Common Stock	120,000	$150.0874	$18.01M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 24,464 shares (Direct); Common Stock — 299,942 shares (Direct); Common Stock — 594,060 shares (Indirect, Trust)

Footnotes (1)

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Includes 201,150 restricted stock units. This transaction was executed in multiple trades at prices ranging from $150.00 to $150.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. Held by Jonathan Goldsmith Revocable Trust. Held by Rebecca Goldsmith Revocable Trust.

Key Figures

Options exercised at $4.09: 23,244 options at $4.09/share Options exercised at $4.73: 96,756 options at $4.73/share Shares sold: 120,000 shares at $150.0874 +4 more

7 metrics

Options exercised at $4.09 23,244 options at $4.09/share Exercise of stock options into common stock on April 15, 2026

Options exercised at $4.73 96,756 options at $4.73/share Exercise of stock options into common stock on April 15, 2026

Shares sold 120,000 shares at $150.0874 Open-market sale of common stock on April 15, 2026

Direct holdings after transaction 276,698 shares Direct common stock position following reported transactions

Restricted stock units included 201,150 RSUs RSUs included within direct holdings after transactions

Indirect trust holding (largest) 594,060 shares Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust

Indirect trust holdings (each) 64,424 shares Held by Jonathan and Rebecca Goldsmith Revocable Trusts

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average price, revocable trust, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 201,150 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"This transaction was executed in multiple trades... The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

revocable trust financial

"Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust."

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

stock option (right to buy) financial

"security_title": "Stock Option (Right to Buy)""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		M(1)		23,244	A	$4.09	299,942(2)	D
Common Stock	04/15/2026		M(1)		96,756	A	$4.73	396,698(2)	D
Common Stock	04/15/2026		S(1)		120,000	D	$150.0874(3)	276,698(2)	D
Common Stock								594,060	I	Trust(4)
Common Stock								64,424	I	Trust(5)
Common Stock								64,424	I	Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.09	04/15/2026		M(1)			23,244	03/13/2023	03/12/2029	Common Stock	23,244	$0	24,464	D
Stock Option (Right to Buy)	$4.73	04/15/2026		M(1)			96,756	08/09/2023	08/08/2029	Common Stock	96,756	$0	424,085	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.

2. Includes 201,150 restricted stock units.

3. This transaction was executed in multiple trades at prices ranging from $150.00 to $150.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

5. Held by Jonathan Goldsmith Revocable Trust.

6. Held by Rebecca Goldsmith Revocable Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Mark A. Goldsmith report at Revolution Medicines (RVMD)?

Mark A. Goldsmith exercised stock options for 120,000 Revolution Medicines shares and then sold 120,000 common shares. The sales occurred at a weighted average price of $150.0874 per share in open-market transactions on April 15, 2026, under a Rule 10b5-1 trading plan.

At what prices were Mark A. Goldsmith’s options in Revolution Medicines (RVMD) exercised?

Goldsmith exercised two tranches of stock options in Revolution Medicines. He exercised 23,244 options at an exercise price of $4.09 per share and 96,756 options at $4.73 per share, receiving an equal number of common shares upon conversion of these derivative securities.

How many Revolution Medicines (RVMD) shares did Mark A. Goldsmith sell and at what price?

He sold 120,000 shares of Revolution Medicines common stock. The transactions were executed in multiple trades at prices ranging from $150.00 to $150.64 per share, with a reported weighted average sale price of $150.0874 per share, as described in the filing footnote.

Were Mark A. Goldsmith’s Revolution Medicines (RVMD) share sales pre-planned?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024. Such plans allow insiders to schedule trades in advance, reducing the significance of trade timing as an information signal.

How many Revolution Medicines (RVMD) shares does Mark A. Goldsmith hold after these transactions?

After the reported transactions, Goldsmith holds 276,698 Revolution Medicines common shares directly, including 201,150 restricted stock units. He also has indirect holdings through three revocable trusts, with reported positions of 594,060, 64,424, and 64,424 common shares in those trust accounts.

What do the trust holdings in the Revolution Medicines (RVMD) Form 4 represent?

The filing shows indirect ownership through trusts. Shares are held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust, the Jonathan Goldsmith Revocable Trust, and the Rebecca Goldsmith Revocable Trust, reflecting family-related ownership structures rather than additional direct trading activity.